Coherus Oncology CHRS
Coherus Oncology reported a net loss of $39.33 million
Coherus Oncology (CHRS) filed a 10-Q with the SEC on Nov 9, 2026, 4:59 pm ET. Source: the filing on SEC EDGAR.
Quarterly report for the period ended Sep 30, 2026, 4 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001104659-26-124572
- Revenue was $14.27 million for the three months ended Sep 30, 2026
- Diluted EPS was -$0.25 for the three months ended Sep 30, 2026
- Cash and equivalents were $53.49 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
Going-concern warning is new
“After considering these plans and the guidance within ASC 205-40, the Company concluded that substantial doubt about its ability to continue as a going concern had not been alleviated for the one-year period following the issuance of these condensed consolidated…”
First warning: the prior 10-Q (filed Aug 5, 2026) had no going-concern warning. Prior report Prior on EDGAR
Quoted from the filing.
What changed since last quarter
4 new risk factors · 4 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change QoQ | |
|---|---|---|---|
| Operating income and margin | −$33.65M | −$32.33M | −4.1% |
| Net income | −$39.33M | −$20.63M | −91% |
| Operating cash flow | −$34.02M | −$62.09M | +45% |
| Cash | $53.49M | $82.92M | −36% |
New risk factors (4)
- Our expected future operating losses and negative operating cash flows, together with our need for additional funding to support planned operations, raise substantial doubt about our ability to continue as a going concern. We continue to be dependent on the ability to raise funds. This additional funding may not be… +4 more paragraphs
- The Net Sales reported to us by the Intas Parties from July 1, 2025 through September 30, 2026 came very close to meeting the threshold for the first Earnout Payment, with the "true-up" process ongoing. We are exercising our audit and other contractual rights to assess the Intas Parties' report.
- We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered…
- Further, the 2031 Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict our ability to incur liens, incur additional indebtedness, make investments, engage in certain mergers and acquisitions or asset sales, and…
Removed risk factors (4)
- We continue to be dependent on the ability to raise funds. This additional funding may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development and commercialization efforts or other operations. +2 more paragraphs
- If we are unable to obtain funding on a timely basis or at all, maintain and grow sales of LOQTORZI, stay profitable or generate any net profits, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product or product…
- expanded rebate payments under the MDRP to include utilization by individuals enrolled in Medicaid managed care organizations; added a provision to increase the Medicaid rebate for line extension drugs; established annual fees and taxes on manufacturers of certain branded prescription drugs; and expanded the entities…
- In addition, state laws govern the privacy and security of personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. By way of example, California enacted the California Consumer Privacy Act as…